Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,040,172
  • Shares Outstanding, K 179,071
  • Annual Sales, $ 1,491 M
  • Annual Income, $ -77,210 K
  • 60-Month Beta 1.36
  • Price/Sales 9.96
  • Price/Cash Flow 387.48
  • Price/Book 5.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.05
  • Number of Estimates 7
  • High Estimate 0.01
  • Low Estimate -0.08
  • Prior Year -0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.41 +3.72%
on 07/08/19
88.09 -6.50%
on 06/21/19
+1.53 (+1.89%)
since 06/14/19
3-Month
79.41 +3.72%
on 07/08/19
90.61 -9.09%
on 05/16/19
-6.15 (-6.94%)
since 04/16/19
52-Week
79.13 +4.09%
on 12/26/18
106.74 -22.84%
on 10/17/18
-20.37 (-19.82%)
since 07/16/18

Most Recent Stories

More News
BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 1,...

BMRN : 82.24 (-2.08%)
Watch for Biomarin Pharmac to Potentially Pullback After Gaining 2.91% Yesterday

Biomarin Pharmac (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $83.87 to a high of $85.55. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high...

BMRN : 82.24 (-2.08%)
BioMarin (BMRN) to File for Hemophilia A Candidate in Q4

BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.

SGMO : 11.66 (-2.83%)
ONCE : 97.79 (-0.21%)
BMRN : 82.24 (-2.08%)
PFE : 42.85 (+0.23%)
BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical veteran and former Johnson & Johnson executive,...

JNJ : 132.43 (-1.69%)
BMRN : 82.24 (-2.08%)
Sarepta Stock Up Almost 40% This Year So Far: Here's Why

Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.

SRPT : 153.28 (-2.31%)
AYTU : 1.76 (-0.56%)
BMRN : 82.24 (-2.08%)
AXGT : 7.57 (+2.85%)
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that based on recent meetings with health authorities in the U.S. and Europe, the company plans to submit marketing applications to both the...

BMRN : 82.24 (-2.08%)
SmarTrend Watching for Potential Rebound in Shares of Biomarin Pharmac After 2.58% Loss

Biomarin Pharmac (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $81.98 to a high of $83.65. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of...

BMRN : 82.24 (-2.08%)
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and principal investigator for the valoctocogene...

BMRN : 82.24 (-2.08%)
Biomarin Pharmac Set to Possibly Rebound After Yesterday's Selloff of 1.30%

Biomarin Pharmac (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $84.78 to a high of $86.09. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of...

BMRN : 82.24 (-2.08%)
BioMarin Gets $15M From Pfizer on Talzenna's European Nod

BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.

ANIK : 40.88 (+1.34%)
BMRN : 82.24 (-2.08%)
ACOR : 6.91 (+5.34%)
PFE : 42.85 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BMRN with:

Business Summary

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment...

See More

Key Turning Points

2nd Resistance Point 84.92
1st Resistance Point 84.45
Last Price 82.24
1st Support Level 83.09
2nd Support Level 82.20

See More

52-Week High 106.74
Fibonacci 61.8% 96.19
Fibonacci 50% 92.93
Fibonacci 38.2% 89.68
Last Price 82.24
52-Week Low 79.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar